'김갑성' 기자의 전체기사
-
'Scripting Possibilities' in Biotechnology: Global Innovators…
PISCATAWAY, N.J., Jan. 6, 2026 -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech Global Forum, scheduled for January 14, 2026, at the San Francisco Marriott Marquis, with both in-person and virtual attendance options available. Now in its fifth year, GenScript Biotech Global Forum has become a convening platform to push the boundaries of what's possible for the global biotech ecosystem. Held alongside the annual J.P. Morgan Healthcare Conference week, the Forum brings together the s
- 김갑성 기자
- 2026-01-06 21:30
-
Healthcare Holding Schweiz Acquires Stake in Medddbase…
Healthcare Holding Schweiz AG, a leading service provider and distributor of medical technology in Switzerland, expands its portfolio through the acquisition of a majority stake in Medddbase International AG, which includes Medddbase Schweiz AG and Medddbase Deutschland GmbH. Healthcare Holding Schweiz is managed by Winterberg Advisory GmbH and KKA Partners. BAAR, Switzerland, Jan. 6, 2026 -- Healthcare Holding Schweiz AG has successfully acquired a majority interest in Medddbase International AG, headquartered in Buchs, St. Gallen. Medddbase is a highly specialized service pro
- 김갑성 기자
- 2026-01-06 19:19
-
Clarivate Identifies Eleven Potential Blockbuster and Transfo…
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, Jan. 6, 2026 -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant clinical impact and strong commercial potential over the coming year. The annual analysis highlights therapies expected to reshape treatment approaches across metabolic disease, oncology, immunology, rare conditions and neurological dis
- 김갑성 기자
- 2026-01-06 16:21
-
Ark Biopharmaceutical Receives China Marketing Authorizatio…
SHANGHAI, Jan. 6, 2026 -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Azstarys®) for treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older in China. Azstarys® is a central nervous system stimulant indicated for the treatment of ADHD. Each once-daily capsule contains serdexmethylphenidate (SDX), a prodrug of dexmethy
- 김갑성 기자
- 2026-01-06 14:45
-
Esco Aster Signs Exosome Clinical cGMP Manufacturing Con…
SINGAPORE, Jan. 6, 2026 -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster's cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On's IND submission. The IND was cleared by the U.S. FDA in Q1 2025. &
- 김갑성 기자
- 2026-01-06 12:03
-
Everest Medicines to Present at the 44th Annual J.P. Morgan H…
SHANGHAI, Jan. 6, 2026 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Ian Woo, President and Chief Financial Officer, will present a company update and that the management team including chairman Bill Wu and Chief Executive Officer Rogers Luo will participate in one-on-one meetings at the 44th Annual J.P. Morgan Healthcare Conference being held January 12-15, 2026, in San Francisco: 44th
- 김갑성 기자
- 2026-01-06 07:58
-
Kelun-Biotech Receives Investigational New Drug Approval fo…
CHENGDU, China, Jan. 5, 2026 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumors. In December 2025, Kelun-Biotech and Crescent Biopharma, Inc. ("Cresc
- 김갑성 기자
- 2026-01-05 20:00
-
Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY…
[ 메디채널 김갑성 기자 ] Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices (EBD), injectables, diagonostics, and other complementary solutions, today announced that its long-acting botulinum toxin type A product, DAXXIFY (trademark in Chinese Mainland达希斐®), has passed the quality testing from National I
- 김갑성 기자
- 2026-01-05 17:36
-
Kelun-Biotech Announces Breakthrough Therapy Designa…
CHENGDU, China, Jan. 5, 2026 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) in combination with MSD's anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[1]) was granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of patients with locally ad
- 김갑성 기자
- 2026-01-05 17:29
-
GenEditBio Receives FDA Clearance of IND Application for Its Le…
HONG KONG, Jan. 5, 2026 -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to initiate Phase 1/2 CLARITY trial activities for its lead in vivo genome-editing program GEB-101 for TGFBI corneal dystrophy. The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients with TGFBI
- 김갑성 기자
- 2026-01-05 12:07
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 5하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 6만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 8대한약물영양의학회 2020년 추계학술대회
- 92021년 대학생기자단 모집
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-01-07_WED
2026-01-06_TUE
- NYSE Content Advisory: Pre-Market Update + NYSE Visits CES 2026 in Las Vegas to Talk AI, Tech, Robotics 21:55
- 'Scripting Possibilities' in Biotechnology: Global Innovators Converge in San Francisco for GenScript's 5th Annual Biotech Forum During JPM Week 21:30
- Segway Elevates Personal Mobility With Smarter, More Powerful Innovations at CES 2026 21:00
- COCOS 4 が登場、完全にオープンソース化 20:25
- REDMAGIC Astra Gaming Tablet Arrives in Korea with Snapdragon 8 Elite and 165Hz OLED 20:00
- IBM Announces Long-Term Renewal as the Official AI, Cloud and Digital Transformation Partner for The All England Lawn Tennis Club 20:00
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 01월 07일 04시 20분